[Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression]

Autor: Adalberto Benito-Hernández, María Victoria Oviedo, Luis Martín-Penagos, Jaime Mazón, Marina de Cos, Emilio Rodrigo, David San Segundo, Juan Carlos Ruiz, Marcos López-Hoyos, Gema Fernández-Fresnedo, Javier Gómez-Román

Publikováno v: Nefrología Vol. 41. Issue. 3.May-June 2021 pages 227-366
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Nefrología (English Edition), Vol 41, Iss 3, Pp 311-320 (2021)
Web of Science

Background and objective: About 25% of patients with IgA nephropathy (IgAN) progress to stage 5 chronic kidney disease (CKD) after years of evolution. Various tools have been developed in recent years designed to predict which of the patients will ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d74a397561a0a2f94aae373f46d2e0d4
https://pubmed.ncbi.nlm.nih.gov/33741175